PRODUCT TYPES – Page 7

Cell viability failure during ATMP manufacturing: regulatory risk assessment and CAPA

The first step in addressing cell viability failures is recognizing the symptoms or signals occurring either on the manufacturing floor or in the quality control laboratory. Common indicators include:Click to…

API hygroscopicity-driven degradation after re-crystallization parameter adjustment: risk-based approach to prevent repeat OOS across future API batches

Symptoms of API hygroscopicity-driven degradation may manifest during various stages of the production process or in finished product testing. Common indicators include:Click to read the full article.

Aseptic manipulation deviation during FDA inspection readiness: patient safety impact and disposition

Identifying symptoms of aseptic manipulation deviations early is key to ensuring patient safety and regulatory compliance. Common signals include:Click to read the full article.

API color / appearance change during stability pull at 6/12 months: supplier qualification gaps and incoming testing upgrades to close the loop

The onset of color or appearance changes in APIs can manifest in various ways. Symptoms observed may include:Click to read the full article.

Cryopreservation failure during tech transfer: inspection-ready investigation package

Identifying symptoms of cryopreservation failure during tech transfer is paramount to implementing swift corrective actions. Typical signals may include:Click to read the full article.

API particle size distribution failure during FDA inspection readiness: risk-based approach to prevent repeat OOS across future API batches

Identifying symptoms or signals that an API's particle size distribution may not meet specifications is the first step in investigating a PSD failure. Symptoms may arise during various stages of…

Cell viability failure during scale-up: regulatory risk assessment and CAPA

Detecting cell viability failures hinges on keen observation and systematic data collection. Common symptoms of inadequate cell viability during scale-up include:Click to read the full article.

API bulk density variability during EU GMP inspection preparation: root cause analysis (process vs lab) with CAPA effectiveness checks

Identifying symptoms early is vital in managing bulk density variability effectively. Symptoms may present in various forms, influencing batch quality and regulatory compliance. Below are some signals indicating potential issues…

Aseptic manipulation deviation during stability testing: inspection-ready investigation package

The first step in investigating an aseptic manipulation deviation is to identify key symptoms or signals that may indicate a deviation. These could manifest in various forms during stability testing:Click…

API particle size distribution failure after cleaning validation requalification: control strategy updates for CPPs/CMAs and continued process verification

Identifying the initial symptoms of an API particle size distribution failure is crucial for timely investigation and resolution. Common signals may include:Click to read the full article.

Aseptic manipulation deviation during tech transfer: patient safety impact and disposition

Understanding the symptoms or signals that indicate a potential aseptic manipulation deviation is the first step in initiating an investigation. These signals can manifest in various ways during the tech…

API residual palladium OOS during routine release testing: supplier qualification gaps and incoming testing upgrades to close the loop

Identifying symptoms of OOS results is critical in the early stages of investigation. Some immediate flags that may indicate a residual palladium OOS situation include:Click to read the full article.